DTIL

Rating neutralAI MemoPost-earnings T+3

Precision BioSciences

As of 2026-05-16/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-05-16 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

EASL 2026 PBGENE-HBV poster is the clearest near-term value inflection • 2026-05-30

Expected move: +13%

Biggest risk

The earnings follow-up did not provide new efficacy readouts or formal guidance upgrades; revenue strength was milestone-driven, non-cash fair-value swings still distorted results, and the company explicitly warns runway assumptions may prove imprecise. Post-print analyst revision evidence is unavailable in the packet and was not confirmed from primary sources, so this remains a monitoring setup rather than a conviction upgrade.

Invalidation

Break below $5 or thesis failure.

What would change my mind?

The Q1 update modestly improved the operating case: cash of $125.8 million and management's runway-through-2028 statement reduce immediate dilution pressure, while PBGENE-HBV patient exposure and the upcoming EASL biopsy poster give the stock a tangible near-term clinical hook [#10-Q-2026-05-05].

Research note

Recommendation

neutral

Confidence

medium

As of

2026-05-16

Base target

p=1%

Bull target

$12

p=0%

Bear target

p=0%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Post-Q1 earnings digestion centers on runway durability and execution proof points
FUNCTION-DMD first multi-patient human data remains the major longer-horizon swing factor
Runway-through-2028 claim remains a financing checkpoint rather than a resolved overhang

BearKey bullets

Clinical readout risk is still dominant: the HBV program is early, cohort optimization is ongoing, and EASL biopsy data may not translate into a clearly derisked efficacy path.
DMD execution risk remains high because the program is only at first-site activation/enrollment stage and meaningful multi-patient human data are not expected until late 2026.
Even the closer peer set is imperfect because public gene-editing companies differ by modality, indication, stage, and balance-sheet scale, so peer valuation should not be treated as strong evidence.

WatchKey bullets

EASL 2026 PBGENE-HBV poster is the clearest near-term value inflection

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $8 (p=1%)

Bull/Bear spread: +73% / -35%

Vs latest close: Bull +73% · Base +13% · Bear -35%

Scenario probabilities

Bull Target: $12 (p=0%)Base Target: $8 (p=1%)Bear Target: $5 (p=0%)

Commentary

This remains a cautious post-earnings follow-up. Despite the queue metadata citing May 13, 2026, the company's primary-source earnings release and 8-K were filed on May 5, 2026 [#8-K-2026-05-05]. The immediate price reaction was mixed: DTIL closed at 7.45 on May 5 versus 7.63 on May 4, then recovered to 8.20 by May 12, so the market appears to have absorbed the earnings print as supportive on runway but still dependent on upcoming clinical evidence. Headline flow has been active and mostly company-generated, confirmed post-print analyst target/rating revisions remain limited or unavailable, and even closer gene-editing peers are only partial comparators, which keeps conviction capped.

As of 2026-05-16 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Post-Q1 earnings digestion centers on runway durability and execution proof points
FUNCTION-DMD first multi-patient human data remains the major longer-horizon swing factor
Runway-through-2028 claim remains a financing checkpoint rather than a resolved overhang

Scenarios

Bull Target (Scenario probability)

$12 / p=0% prob

Base Target (Scenario probability)

$8 / p=1% prob

Bear Target (Scenario probability)

$5 / p=0% prob

Price $7 as of 2026-05-28

Nearest Scenario: Base (∆ 13%)

Targets vs latest close: Bull +73% · Base +13% · Bear -35%

Sentiment & Exposure

News Sentiment (30d)

0.20

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-05-30
EASL 2026 PBGENE-HBV poster is the clearest near-term value inflection
Management said a late-breaking EASL Congress 2026 poster will present first evidence of elimination and inactivation of cccDNA in liver biopsies from PBGENE-HBV-treated chronic hepatitis B patients. Because DTIL remains an early clinical gene-editing story, investor reaction will likely depend more on biopsy/biomarker credibility and safety interpretation than on the Q1 financial print itself [#10-Q-2026-05-05].
Prob 62.00% • Move 28.00% • Priced-in 42.00%

Short-term Catalysts

Next few weeks

Post-Q1 earnings digestion centers on runway durability and execution proof points
2026-06-30
On May 5, 2026, Precision reported Q1 revenue of $10.8 million, cash/cash equivalents/restricted cash of $125.8 million, and said existing cash plus operating discipline and ATM availability should fund operations and PBGENE-HBV/PBGENE-DMD data milestones through 2028. The same update also pushed PBGENE-HBV cumulative exposure to 16 patients and 38 administrations across five cohorts. That helps near-term financing anxiety, but the setup still needs clinical follow-through to sustain sentiment [#8-K-2026-05-05] [#10-Q-2026-05-05].
Prob 68% • Move 10% • Priced-in 58%

Long-term Catalysts

Months to a year

FUNCTION-DMD first multi-patient human data remains the major longer-horizon swing factor
2026-12-31
Precision had activated Arkansas Children's Hospital as its first FUNCTION-DMD site and was actively enrolling patients as of the May 5 business update, while the 2025 10-K said initial data from multiple patients are expected by year-end 2026 with safety and early efficacy assessed by near full-length dystrophin expression from muscle biopsies. This is the clearest distinct long-horizon program catalyst, but also the highest binary execution risk in the story [#10-Q-2026-05-05] [#10-K-2026-03-12].
Prob 46% • Move 42% • Priced-in 27%
Runway-through-2028 claim remains a financing checkpoint rather than a resolved overhang
2028-12-31
Precision says cash, operating discipline, and ATM availability should fund key PBGENE-HBV and PBGENE-DMD milestones through 2028, which gives the company time to reach clinical data before an obvious financing wall. The quality of that runway still depends on spend control, ATM access, and whether clinical development broadens after data, so this is a risk-management catalyst rather than a clean upside driver [#10-Q-2026-05-05].
Prob 57% • Move 14% • Priced-in 55%

Risks

Clinical readout risk is still dominant: the HBV program is early, cohort optimization is ongoing, and EASL biopsy data may not translate into a clearly derisked efficacy path.
DMD execution risk remains high because the program is only at first-site activation/enrollment stage and meaningful multi-patient human data are not expected until late 2026.
Even the closer peer set is imperfect because public gene-editing companies differ by modality, indication, stage, and balance-sheet scale, so peer valuation should not be treated as strong evidence.
Runway has improved, but management's through-2028 statement depends on operating discipline and ATM availability, and the 10-Q says capital could be used sooner than expected [#10-Q-2026-05-05].
The Q1 revenue jump was largely driven by milestone/licensing revenue rather than recurring product revenue, limiting how much the earnings print changes fundamental valuation support.

Peers

Symbol	Summary
BEAM	Beam Therapeutics is a closer gene-editing-platform comparator than the same-market-cap peer list because investor sentiment is driven by clinical editing proof, safety, durability, and cash runway; it is still not a direct HBV or DMD indication match.
EDIT	Editas Medicine is a direct public gene-editing development-stage comparator for platform credibility, regulatory risk, and binary clinical-data valuation, though its program mix differs from Precision's ARCUS HBV and DMD focus.
NTLA	Intellia Therapeutics is a larger in vivo gene-editing comparator that helps frame platform-risk sentiment and clinical-readout expectations, but its scale and pipeline breadth make it an imperfect valuation peer for low-market-cap DTIL.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Human targets: serper
Analysis date: 2026-05-16

AI Stock Memo: DTIL - Precision BioSciences - RankAlpha